SCHEMBL2311252

SCHEMBL2311252

NC(CO)C(=O)Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.55
POLB P06746 1/20 0.53
MEN1 O00255 3/20 0.53
ALDH1A1 P00352 3/20 0.53
MAPT P10636 3/20 0.53
KMT2A Q03164 3/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TAAR1 Q96RJ0 1/20 0.50
LTA4H P09960 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
ATM Q13315 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
TP53 P04637 1/20 0.48
EPHX1 P07099 1/20 0.48
TSHR P16473 1/20 0.48
EPHX2 P34913 1/20 0.48
CDK9 P50750 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8526953 1.00 SPHK1 (0.55) SPHK1POLBMEN1ALDH1A1MAPT
SCHEMBL8526956 1.00 SPHK1 (0.55) SPHK1POLBMEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL20569864 0.98 SPHK1 (0.54) SPHK1POLBMEN1ALDH1A1MAPT
SCHEMBL8607633 0.87 KMT2A (0.46) SPHK1POLBMEN1ALDH1A1MAPT
SCHEMBL29410403 0.85 POLB (0.53) POLBMEN1ALDH1A1MAPTKMT2A
SCHEMBL10791327 0.83 MEN1 (0.60) POLBMEN1ALDH1A1MAPTKMT2A
SCHEMBL5072176 0.83 MME (0.53) POLBMEN1ALDH1A1MAPTKMT2A
SCHEMBL14209990 0.83 MEN1 (0.60) POLBMEN1ALDH1A1MAPTKMT2A
SCHEMBL5270163 0.83 MEN1 (0.60) POLBMEN1ALDH1A1MAPTKMT2A
SCHEMBL3954076 0.83 LTA4H (0.67) POLBMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A SPHK1 1669/4885POLB 3239/4885MEN1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.